Kengrexal (Cangrelor Tetrasodium)

Cangrelor acts by reversibly binding to the platelet P2Y12 ADP receptor. This blocks ADP‑mediated activation of the GPIIb/IIIa complex, preventing platelet activation and aggregation, which results in a fast‑acting antiplatelet effect that can be quickly discontinued when the infusion stops.

The dosing regimen for Kengrexal is determined by the prescribing clinician based on the specific clinical scenario, patient characteristics, and procedural requirements. Healthcare professionals set the infusion rate and duration according to approved guidelines and individual patient needs.

Safety of Cangrelor in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Kengrexal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Compared with oral P2Y12 inhibitors such as clopidogrel or ticagrelor, Kengrexal offers an intravenous route with a rapid onset of action and a short, reversible half‑life. This allows precise control of platelet inhibition during PCI, whereas oral agents have slower onset and longer duration, which may be less suitable for procedures requiring immediate platelet modulation.

Kengrexal must be stored at 2‑8 °C in a refrigerator. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold‑chain ensures the stability and efficacy of the injectable solution.

Kengrexal is administered intravenously by a qualified healthcare professional. It is typically given as a bolus followed by a continuous infusion during the PCI procedure, allowing rapid achievement of platelet inhibition that can be stopped immediately when the infusion ends.

The most serious risks include severe or uncontrolled bleeding, thrombocytopenia, and hypersensitivity reactions such as anaphylaxis. Clinicians should monitor patients closely for signs of bleeding, changes in platelet counts, and any allergic manifestations throughout the infusion.

Kengrexal should not be used in patients with active severe bleeding, known hypersensitivity to cangrelor or any component of the formulation, or in those where rapid platelet inhibition is contraindicated. Caution is also advised in patients with severe hepatic impairment.